David Shaw’s ANI Pharmaceuticals ANIP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $14.5M | Sell |
174,732
-38,701
| -18% | -$3.1M | 0.01% | 1537 |
|
|
2026
Q1 | $16.4M | Sell |
213,433
-40,103
| -16% | -$3.13M | 0.01% | 1276 |
|
|
2025
Q4 | $20M | Buy |
253,536
+40,530
| +19% | +$3.51M | 0.01% | 1241 |
|
|
2025
Q3 | $19.5M | Buy |
213,006
+144,714
| +212% | +$11.8M | 0.01% | 1192 |
|
|
2025
Q2 | $4.46M | Sell |
68,292
-161,409
| -70% | -$10.5M | ﹤0.01% | 2119 |
|
|
2025
Q1 | $15.4M | Buy |
229,701
+33,382
| +17% | +$1.99M | 0.01% | 1093 |
|
|
2024
Q4 | $10.9M | Buy |
196,319
+87,698
| +81% | +$5.03M | 0.01% | 1440 |
|
|
2024
Q3 | $6.48M | Buy |
108,621
+99,861
| +1,140% | +$6.09M | 0.01% | 1752 |
|
|
2024
Q2 | $558K | Buy |
+8,760
| New | +$569K | ﹤0.01% | 3562 |
|
|
2022
Q2 | – | Sell |
-14,653
| Closed | -$412K | – | 5318 |
|
|
2022
Q1 | $412K | Sell |
14,653
-21,286
| -59% | -$794K | ﹤0.01% | 4481 |
|
|
2021
Q4 | $1.66M | Buy |
35,939
+18,424
| +105% | +$792K | ﹤0.01% | 3524 |
|
|
2021
Q3 | $575K | Sell |
17,515
-7,399
| -30% | -$230K | ﹤0.01% | 4006 |
|
|
2021
Q2 | $873K | Sell |
24,914
-13,832
| -36% | -$471K | ﹤0.01% | 3652 |
|
|
2021
Q1 | $1.4M | Buy |
38,746
+12,286
| +46% | +$385K | ﹤0.01% | 2856 |
|
|
2020
Q4 | $768K | Buy |
+26,460
| New | +$758K | ﹤0.01% | 3187 |
|
|
2020
Q2 | – | Sell |
-16,523
| Closed | -$673K | – | 3966 |
|
|
2020
Q1 | $673K | Sell |
16,523
-20,482
| -55% | -$1.09M | ﹤0.01% | 3028 |
|
|
2019
Q4 | $2.28M | Buy |
37,005
+2,756
| +8% | +$183K | ﹤0.01% | 2358 |
|
|
2019
Q3 | $2.5M | Buy |
34,249
+18,892
| +123% | +$1.41M | ﹤0.01% | 2196 |
|
|
2019
Q2 | $1.26M | Buy |
15,357
+8,255
| +116% | +$587K | ﹤0.01% | 2536 |
|
|
2019
Q1 | $501K | Buy |
7,102
+1,308
| +23% | +$77K | ﹤0.01% | 3002 |
|
|
2018
Q4 | $261K | Buy |
5,794
+700
| +14% | +$36.7K | ﹤0.01% | 3427 |
|
|
2018
Q3 | $288K | Buy |
+5,094
| New | +$312K | ﹤0.01% | 3375 |
|
|
2015
Q3 | – | Sell |
-15,000
| Closed | -$931K | – | 3711 |
|
|
2015
Q2 | $931K | Sell |
15,000
-21,829
| -59% | -$1.3M | ﹤0.01% | 2762 |
|
|
2015
Q1 | $2.3M | Buy |
36,829
+23,429
| +175% | +$1.43M | ﹤0.01% | 1897 |
|
|
2014
Q4 | $756K | Buy |
+13,400
| New | +$591K | ﹤0.01% | 3035 |
|
|
2014
Q3 | – | Sell |
-13,039
| Closed | -$449K | – | 4080 |
|
|
2014
Q2 | $449K | Buy |
13,039
+3,699
| +40% | +$116K | ﹤0.01% | 3615 |
|
|
2014
Q1 | $293K | Buy |
+9,340
| New | +$248K | ﹤0.01% | 3918 |
|
|
2013
Q3 | – | Sell |
-3,927
| Closed | -$24K | – | 4265 |
|
|
2013
Q2 | $24K | Buy |
+3,927
| New | +$27.5K | ﹤0.01% | 3934 |
|
Other funds holding ANIP
SCM
TCM
GACM
David Shaw's ANIP Position: Q2 2026 in Review
David Shaw reduced its ANI Pharmaceuticals (ANIP) stake by 18% in Q2 2026, selling an estimated $3.1M and leaving 174,732 shares worth $14.5M. The position accounts for 0.01% of the portfolio, ranked #1537.
David Shaw first reported a position in ANIP in Q2 2013 and has held it in 28 quarters since. The position peaked at $20M in Q4 2025. 305 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.
- David Shaw held 174,732 shares of ANI Pharmaceuticals worth $14.5M as of Q2 2026.
- David Shaw sold 38,701 ANI Pharmaceuticals shares in Q2 2026, an estimated $3.1M.
- ANI Pharmaceuticals made up 0.01% of David Shaw's portfolio in Q2 2026, its #1537 holding.
- David Shaw first reported a position in ANI Pharmaceuticals in Q2 2013 and has held it in 28 quarters since.
- David Shaw's ANI Pharmaceuticals position peaked at $20M in Q4 2025.
- 305 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.
Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.